Lundbeck Convinces NICE To Back Brintellix In MDD
This article was originally published in Scrip
NICE has decided to recommend H. Lundbeck AS' Brintellix (vortioxetine) for funding on the National Health Service in England and Wales after requesting and receiving more information from the Danish company on the novel antidepressant.
You may also be interested in...
The Nordic region’s vibrant life sciences ecosystem will be the chief focus for newly created Eir Ventures, a strategic partnership and investment company.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.